Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

Clinical and Applied Thrombosis/Hemostasis

Volumn 22, Issue 1, 2016, Pages 12-20

  Elsallabi, Osama ^a   Bhatt, Vijaya Raj ^b   Dhakal, Prajwal ^c   Foster, Kirk W ^b   Tendulkar, Ketki K ^b  

^a CREIGHTON UNIVERSITY   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c TRIBHUVAN UNIVERSITY   (Nepal)

Author keywords

calcineurin inhibitor; complement blockade; graft versus host disease; hematopoietic stem cell transplant; thrombotic microangiopathy

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; COMPLEMENT; CORTICOSTEROID; CREATININE; CYCLOSPORIN; CYSTATIN C; DACLIZUMAB; ECULIZUMAB; HAPTOGLOBIN; IOHEXOL; LACTATE DEHYDROGENASE; MYCOPHENOLATE MOFETIL; RAPAMYCIN; RITUXIMAB; TACROLIMUS;

ARTICLE; BLOOD CLOTTING; BLOOD PRESSURE MONITORING; COMPLEMENT ACTIVATION; COOMBS TEST; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG WITHDRAWAL; EARLY DIAGNOSIS; ENDOTHELIUM INJURY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYSIS; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; KIDNEY FUNCTION TEST; LACTATE DEHYDROGENASE BLOOD LEVEL; MORTALITY RATE; NEUROLOGIC DISEASE; OPPORTUNISTIC INFECTION; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN URINE LEVEL; PROTEINURIA; RISK FACTOR; SCREENING TEST; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TISSUE INJURY; TREATMENT OUTCOME; ADVERSE EFFECTS; FEMALE; GRAFT VS HOST DISEASE; MALE; PATHOLOGY; PLASMA EXCHANGE; THROMBOTIC MICROANGIOPATHIES; TRANSPLANTATION CONDITIONING;

FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; PLASMA EXCHANGE; RISK FACTORS; RITUXIMAB; THROMBOTIC MICROANGIOPATHIES; TRANSPLANTATION CONDITIONING;

EID: 84951271153     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029615598221     Document Type: Article

References (78)

1. George JN,. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood. 2010; 116 (20): 4060-4069.
2. George JN, Li X, McMinn JR, Terrell DR, Vesely SK, Selby GB,. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma. Transfusion. 2004; 44 (2): 294-304.
3. Cho BS, Yahng SA, Lee SE, et al. Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation. Transplantation. 2010; 90 (8): 918-926.
4. Daly AS, Hasegawa WS, Lipton JH, Messner HA, Kiss TL,. Transplantation-associated thrombotic microangiopathy is associated with transplantation from unrelated donors, acute graft-versus-host disease and venoocclusive disease of the liver. Transfus Apher Sci. 2002; 27 (1): 3-12.
5. Laskin BL, Goebel J, Davies SM, Jodele S,. Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Blood. 2011; 118 (6): 1452-1462.
6. Martinez MT, Bucher C, Stussi G, et al. Transplant-associated microangiopathy (TAM) in recipients of allogeneic hematopoietic stem cell transplants. Bone Marrow Transplant. 2005; 36 (11): 993-1000.
7. Ho VT, Cutler C, Carter S, et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005; 11 (8): 571-575.
8. Mii A, Shimizu A, Kaneko T, et al. Renal thrombotic microangiopathy associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Pathol Int. 2011; 61 (9): 518-527.
9. Chapin J, Shore T, Forsberg P, Desman G, Van Besien K, Laurence J,. Hematopoietic Transplant-Associated Thrombotic Microangiopathy: Case Report and Review of Diagnosis and Treatments. Clin Adv Hematol Oncol. 2014; 12 (9): 565-573.
10. Batts ED, Lazarus HM,. Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting? Bone Marrow Transplant. 2007; 40 (8): 709-719.
11. Cohen H, Bull HA, Seddon A, et al. Vascular endothelial cell function and ultrastructure in thrombotic microangiopathy following allogeneic bone marrow transplantation. Eur J Haematol. 1989; 43 (3): 207-214.
12. Daly AS, Xenocostas A, Lipton JH,. Transplantation-associated thrombotic microangiopathy: twenty-two years later. Bone Marrow Transplant. 2002; 30 (11): 709-715.
13. Jodele S, Fukuda T, Vinks A, et al. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Biol Blood Marrow Transplant. 2014; 20 (4): 518-525.
14. Laskin BL, Maisel J, Goebel J, et al. Renal arteriolar C4d deposition: a novel characteristic of hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Transplantation. 2013; 96 (2): 217-223.
15. Jodele S, Licht C, Goebel J, et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood. 2013; 122 (12): 2003-2007.
16. Hershko K, Simhadri VL, Blaisdell A, et al. Cyclosporin A impairs the secretion and activity of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeat). J Biol Chem. 2012; 287 (53): 44361-44371.
17. George JN, Li X, McMinn JR, Terrell DR, Vesely SK, Selby GB,. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma. Transfusion. 2004; 44 (2): 294-304.
18. Uderzo C, Bonanomi S, Busca A, et al. Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Transplantation. 2006; 82 (5): 638-644.
19. Fuge R, Bird JM, Fraser A, et al. The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation. Br J Haematol. 2001; 113 (1): 58-64.
20. Holler E, Kolb HJ, Hiller E, et al. Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation. Blood. 1989; 73 (7): 2018-2024.
21. Changsirikulchai S, Myerson D, Guthrie KA, McDonald GB, Alpers CE, Hingorani SR,. Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis. Clin J Am Soc Nephrol. 2009; 4 (2): 345-353.
22. Jodele S, Davies SM, Lane A, et al. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood. 2014; 124 (4): 645-653.
23. Cataland SR, Holers VM, Geyer S, Yang S, Wu HM,. Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP. Blood. 2014; 123 (24): 3733-3738.
24. Laskin BL, Goebel J, Davies SM, et al. Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT. Bone Marrow Transplant. 2011; 46 (5): 682-689.
25. Hingorani S,. Chronic kidney disease in long-term survivors of hematopoietic cell transplantation: epidemiology, pathogenesis, and treatment. J Am Soc Nephrol. 2006; 17 (7): 1995-2005.
26. Mengel M, Sis B, Haas M, et al. Banff 2011 Meeting report: new concepts in antibody-mediated rejection. Am J Transplant. 2012; 12 (3): 563-570.
27. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008; 8 (4): 753-760.
28. Hewamana S, Austen B, Murray J, Johnson S, Wilson K,. Intestinal perforation secondary to haematopoietic stem cell transplant associated thrombotic microangiopathy. Eur J Haematol. 2009; 83 (3): 277-277.
29. Perkowska-Ptasinska A, Sulikowska-Rowinska A, Pazik J, Komuda-Leszek E, Durlik M,. editors. Thrombotic nephropathy and pulmonary hypertension following autologous bone marrow transplantation in a patient with acute lymphoblastic leukemia: case report. Transplant Proc. 2006; 38 (1): 295-296.
30. Siami K, Kojouri K, Swisher KK, Selby GB, George JN, Laszik ZG,. Thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation: an autopsy study. Transplantation. 2008; 85 (1): 22-28.
31. Jodele S, Laskin BL, Dandoy CE, et al. A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. Blood Rev. 2015; 29 (3): 191-204.
32. Ruutu T, Barosi G, Benjamin RJ, et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica. 2007; 92 (1): 95-100.
33. El Seisi S, Gupta R, Clase CM, Forrest DL, Milandinovic M, Couban S,. Renal pathology at autopsy in patients who died after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2003; 9 (11): 683-688.
34. Inamoto Y, Ito M, Suzuki R, et al. Clinicopathological manifestations and treatment of intestinal transplant-associated microangiopathy. Bone Marrow Transplant. 2009; 44 (1): 43-49.
35. Hingorani S,. Chronic kidney disease after pediatric hematopoietic cell transplant. Biol Blood Marrow Transplant. 2008; 14 (1): 84-87.
36. Glezerman IG, Jhaveri KD, Watson TH, et al. Chronic kidney disease, thrombotic microangiopathy, and hypertension following T cell-depleted hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2010; 16 (7): 976-984.
37. Hingorani SR, Seidel K, Lindner A, Aneja T, Schoch G, McDonald G,. Albuminuria in hematopoietic cell transplantation patients: prevalence, clinical associations, and impact on survival. Biol Blood Marrow Transplant. 2008; 14 (12): 1365-1372.
38. Worel N, Greinix HT, Leitner G, et al. ABO-incompatible allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning: close association with transplant-associated microangiopathy. Transfus Apher Sci. 2007; 36 (3): 297-304.
39. Au WY, Ma ES, Lee TL, et al. Successful treatment of thrombotic microangiopathy after haematopoietic stem cell transplantation with rituximab. Br J Haematol. 2007; 137 (5): 475-478.
40. Choi C, Schmaier A, Snell M, Lazarus H,. Thrombotic microangiopathy in haematopoietic stem cell transplantation. Drugs. 2009; 69 (2): 183-198.
41. Kennedy GA, Kearey N, Bleakley S, Butler J, Mudie K, Durrant S,. Transplantation-associated thrombotic microangiopathy: effect of concomitant GVHD on efficacy of therapeutic plasma exchange. Bone Marrow Transplant. 2010; 45 (4): 699-704.
42. Jodele S, Bleesing JJ, Mehta PA, et al. Successful early intervention for hyperacute transplant-associated thrombotic microangiopathy following pediatric hematopoietic stem cell transplantation. Pediatr Transplant. 2012; 16 (2): E39-E42.
43. Wolff D, Wilhelm S, Hahn J, et al. Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease. Bone Marrow Transplant. 2006; 38 (6): 445-451.
44. Corti P,. Defibrotide as a promising treatment for thrombotic thrombocytopenic purpura in patients undergoing bone marrow transplantation. Bone Marrow Transplant. 2002; 29 (6): 542-543.
45. Hahn T, Alam AR, Lawrence D, et al. Thrombotic microangiopathy after allogeneic blood and marrow transplantation is associated with dose-intensive myeloablative conditioning regimens, unrelated donor, and methylprednisolone T-cell depletion. Transplantation. 2004; 78 (10): 1515-1522.
46. Mateos J, Perez-Simon JA, Caballero D, et al. Vincristine is an effective therapeutic approach for transplantation-associated thrombotic microangiopathy. Bone Marrow Transplant. 2006; 37 (3): 337-338.
47. Verbiest A, Pirenne J, Dierickx D,. De novo thrombotic microangiopathy after non-renal solid organ transplantation. Blood Rev. 2014; 28 (6): 269-279.
48. Cutler C, Henry NL, Magee C, et al. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005; 11 (7): 551-557.
49. Furlong T, Storb R, Anasetti C, et al. Clinical outcome after conversion to FK 506(tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities. Bone Marrow Transplant. 2000; 26 (9): 985-991.
50. Boyer NL, Niven A, Edelman J,. Tacrolimus-associated thrombotic microangiopathy in a lung transplant recipient. BMJ Case Rep. 2013; 2013. pii: bcr2012007351. doi:10.1136/bcr-2012-007351.
51. Chhajed PN, Tamm M, Glanville AR,. Role of flexible bronchoscopy in lung transplantation. Semin Respir Crit Care Med. 2004; 25 (4): 31-43.
52. Fishman JA,. Infection in solid-organ transplant recipients. N Engl J Med. 2007; 357 (25): 2601-2614.
53. Legro IR, Shah S, Kaza V., Tacrolimus Induced Hemolytic Uremic Syndrome In: A Lung Transplant Patient. 2010 American Thoracic Society International Conference; May 2010; New Orleans, LA. Abstract.
54. Shayani S, Palmer J, Stiller T, et al. Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant. 2013; 19 (2): 298-304.
55. Sartelet H, Toupance O, Lorenzato M, et al. Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys. Am J Transplant. 2005; 5 (10): 2441-2447.
56. Ferrara JL, Levine JE, Reddy P, Holler E,. Graft-versus-host disease. Lancet. 2009; 373 (9674): 1550-1561.
57. George JN, Terrell DR, Vesely SK, Kremer Hovinga JA, Lammle B,. Thrombotic microangiopathic syndromes associated with drugs, HIV infection, hematopoietic stem cell transplantation and cancer. Presse Med. 2012; 41 (3 pt 2): e177-e188.
58. Iacopino P, Pucci G, Arcese W, et al. Severe thrombotic microangiopathy: an infrequent complication of bone marrow transplantation. Gruppo Italiano Trapianto Midollo Osseo (GITMO). Bone Marrow Transplant. 1999; 24 (1): 47-51.
59. Jodele S, Laskin BL, Goebel J, et al. Does early initiation of therapeutic plasma exchange improve outcome in pediatric stem cell transplant-associated thrombotic microangiopathy? Transfusion. 2013; 53 (3): 661-667.
60. Riedl M, Fakhouri F, Le Quintrec M, et al. Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches. Semin Thromb Hemost. 2014; 40 (4): 444-464.
61. Sarode R, McFarland JG, Flomenberg N, et al. Therapeutic plasma exchange does not appear to be effective in the management of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome following bone marrow transplantation. Bone Marrow Transplant. 1995; 16 (2): 271-275.
62. Carella AM, D'Arena G, Greco MM, Nobile M, Cascavilla N,. Rituximab for allo-SCT-associated thrombotic thrombocytopenic purpura. Bone Marrow Transplantat. 2008; 41 (12): 1063-1065.
63. Marr H, McDonald EJ, Merriman E, et al. Successful treatment of transplant-associated microangiopathy with rituximab. N Z Med J. 2009; 122 (1292): 72-74.
64. Kim SS, Patel M, Yum K, Keyzner A,. Hematopoietic stem cell transplant-associated thrombotic microangiopathy: review of pharmacologic treatment options. Transfusion. 2015; 55 (2): 452-458.
65. Dhakal P, Giri S, Pathak R, Bhatt VR,. Eculizumab in Transplant-Associated Thrombotic Microangiopathy (TA-TMA). ACP National Abstract Competitions [Abstract]. National American College of Physicians Internal Medicine Meeting 2015 April 30-May 2, 2015, Boston, Massachusetts.
66. Barnett ANR, Hadjianastassiou VG, Shaw OJ, et al., editors. Eculizumab for salvage in post-transplant thrombotic microangiopathy. Transplant Int. 2011: 24 (9): 153.
67. Canaud G, Kamar N, Anglicheau D, et al. Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. Am J Transplant. 2013; 13 (8): 2179-2185.
68. Chandran S, Baxter-Lowe L, Olson JL, Tomlanovich SJ, Webber A,. Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation - a case report. Transplant Proc. 2011; 43 (5): 2097-2101.
69. Commereuc M, Karras A, Amrein C, et al. Successful treatment of acute thrombotic microangiopathy by eculizumab after combined lung and kidney transplantation. Transplantation. 2013; 96 (8): e58-e59.
70. Hadaya K, Ferrari-Lacraz S, Fumeaux D, et al. Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am J Transplant. 2011; 11 (11): 2523-2527.
71. McCloskey JK, Girlanda R,. Successful management of calcineurin induced Thrombotic Microangiopathy(TMA) with eculizumab after non- renal solid organ transplantation. Blood. 2013; 122 (21): 1078.
72. Okano M, Sakata N, Ueda S, Takemura T,. Recovery from life-threatening transplantation-associated thrombotic microangiopathy using eculizumab in a patient with very severe aplastic anemia. Bone Marrow Transplant. 2014; 49 (8): 1116-1118.
73. Peffault de Latour R, Xhaard A, Fremeaux-Bacchi V, et al. Successful use of eculizumab in a patient with post-transplant thrombotic microangiopathy. Br J Haematol. 2013; 161 (2): 279-280.
74. Safa K, Logan MS, Batal I, Gabardi S, Rennke HG, Abdi R,. Eculizumab for drug-induced de novo post-transplantation thrombotic microangiopathy: a case report. Clin Nephrol. 2015; 83 (2): 125-129.
75. Wilson CH, Brown AL, White SA, Goodship TH, Sheerin NS, Manas DM,. Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab. Transplantation. 2011; 92 (8): e42-e43.
76. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013; 368 (23): 2169-2181.
77. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006; 355 (12): 1233-1243.
78. Ruutu T, Hermans J, Niederwieser D, et al. Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol. 2002; 118 (4): 1112-1119.